



Healthcare Headline Transactions

Biotechnology / Pharmaceuticals	© pharmacyclics	abbvie	 AbbVie Inc. (NYSE:ABBV) agreed to acquire Pharmacyclics Inc. (NasdaqGS:PCYC) for \$21 billion. Pharmacyclics, Inc. focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products used to treat a variety of illnesses and afflictions. Implied Enterprise Value Multiples: 26.1x Revenues, 150.2x EBITDA
Biotechnology / Pharmaceuticals	Salix PHARMACEUTICALS, INC.	VALEANT	 Valeant Pharmaceuticals agreed to acquire Salix Pharmacauticals Ltd. (NasdaqGS:SLXP) for \$11.1 billion. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases. Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, overthe-counter products, and medical devices including acne and anti-depressants. Implied Enterprise Value Multiples: 11.9x Revenues, 87.5x EBITDA
Medical Devices	Cordis.	Cardinal Health	 Cardinal Health, Inc. (NYSE:CAH) entered into binding offer letter to acquire certain assets of the Cordis business of Johnson & Johnson for \$1.9 billion. The Cordis business segment develops, manufactures, and distributes medical devices. Cardinal Health, Inc., a healthcare services company, supplies pharmaceutical and medical products

Life Sciences and Diagnostics

POLYPORE

Target

Separations Media Business



Acquiror

 3M Company (NYSE:MMM) agreed to acquire the Separations Media segment from Polypore International Inc. (NYSE:PPO) for approximately \$1 billion in cash.


and provides inventory management and data reporting services.


- The target business manufactures microporous membranes and modules for the life sciences segment.
- 3M's Healthcare segment provides medical and surgical supplies; skin health and infection prevention products; drug delivery and health information systems; and dental and orthodontic products.


Acquisition Synopsis


• Implied Enterprise Value Multiple: 4.9x Revenues

• Implied Enterprise Value Multiple: 2.5x Revenues










LTM Stock Price Index



Oct-14

Sep-14

Aug-14

Nov-14

Selected Biotechnology / Pharma Transactions

May-14

Mar-14

Target	Acquiror	Target Description
Adcock Ingram	The Bidvest Group	Adcock Ingram Holdings Limited
Holdings Limited	Limited	manufactures and distributes branded and
		generic prescription medicines.
		Transaction Value: \$511 million
Heptares	Sosei Group	Heptares Therapeutics Ltd. develops drugs to
Therapeutics Ltd.	Corporation	tackle diseases involving the nervous system
		and metabolism.
		Transaction Value: \$400 million
Meritage Pharma,	Shire plc	Meritage Pharma, Inc. develops
Inc.		pharmaceuticals for the treatment of
		gastrointestinal and atopic diseases.
		Transaction Value: \$245 million

Selected Life Sciences / Diagnostics Transactions

Target	Acquiror	Target Description
Synexus Limited	LDC (Managers) Limited	Synexus Limited recruits patients for clinical trials on behalf of sponsors. Transaction Value: \$128 million
Molecular Response, LLC, PDX Business Unit	Crown Bioscience, Inc.	PDX Business Unit of Molecular Response, LLC offers drug discovery and vivo pharmacology services. Transaction Value: NA
Signature Diagnostics AG	Roche Holding AG	Signature Diagnostics AG, a translational oncology and genomics company, develops biobanks in multiple cancers. Transaction Value: NA

Recent TM & Asante Transactions







Feb-15 Selected Healthcare Services Transactions

Jan-15

Target	Acquiror	Target Description
BioRx, LLC	Diplomat	BioRx, LLC provides specialty
	Pharmacy, Inc.	pharmaceuticals, supplies and support
		services.
		Transaction Value: \$350 million
HealthLine	Sy.Med	HealthLine Systems, Inc. provides software
Systems, Inc.	Development, Inc.	for credentialing, contact center, and quality
		management.
		Transaction Value: \$88 million
Jaysec	ResMed Inc.	Jaysec Technologies, LLC provides GoJaysec, a
Technologies, LLC		referral and patient management software.
		Transaction Value: NA

Selected Medical Device Transactions

Target	Acquiror	Target Description
Sorin SpA	Cyberonics Inc.	Sorin S.p.A. produces and distributes medical devices for cardiac surgery and cardiac rhythm dysfunctions. Transaction Value: \$1,364 million
Optos plc	Nikon Corporation	Optos plc, a retinal imaging company, provides diagnostic and treatment devices. Transaction Value: \$400 million
Summit Medical, Inc.	Shore Capital Partners, LLC	Summit Medical, Inc. manufactures medical devices for microsurgery use. Transaction Value: NA

TM Asante Healthcare Partners Contacts







Michael S. Goldman Managing Director mgoldman@tmcapital.com 212-809-1419



Paul R. Smolevitz **Managing Director** psmolevitz@tmcapital.com 212-809-1416

TM Asante Healthcare Partners is a dedicated industry-focused investment banking practice that combines TM Capital's extensive healthcare industry experience with the healthcare investment banking credentials of James McLaren, the co-founder of Asante Partners. TM Capital, a partner-owned investment banking firm based in New York, Boston and Atlanta, has built strong industry expertise over 25 years of completing healthcare M&A and financing transactions. Asante Partners and its predecessor firm have more than two decades of industry knowledge and relationships as a boutique investment bank focused exclusively on healthcare. Together, TM and Asante have completed over 80 healthcare mergers, acquisitions and financings valued at over \$4 billion. For more information, visit www.tmcapital.com/tm-asante.

New York 641 Lexington Avenue 30th Floor New York, NY 10022 Tel: 212.809.1360

Boston 201 Washington Street 32nd Floor Boston, MA 02108 Tel: 617.259.2200

15 Piedmont Center NE Suite 1010 Atlanta, GA 30305 Tel: 404.995.6230

